Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X Autonomous & Electric Vehicles — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.41 (market cap $5.07B), while Global X Autonomous & Electric Vehicles trades at $36.14. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| ACAD | DRIV | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.41 | $42.53 |
52-Week Low | $20.06 | $25.23 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
DRIV trades at $36.14, up 1.6% today, with technical indicators showing a bullish trend supported by moving averages, though RSI suggests potential overbought conditions. The stock's support and resistance levels are tightly clustered around $35-$36. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by rising fuel prices and supportive policies, which may benefit DRIV's sector exposure.
The outlook for DRIV is positive due to favorable industry trends, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed, with technical strength offset by valuation concerns. Investors should weigh growth potential against execution risks in the evolving EV market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
